BFM
ALXN

Boothbay Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boothbay Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,296
Closed -$9.61M – 2419
2021
Q2 		$9.61M Buy
52,296
+25,110
+92% +$4.31M 0.31% 59
2021
Q1 		$4.16M Buy
27,186
+12,579
+86% +$1.95M 0.16% 133
2020
Q4 		$2.28M Buy
+14,607
New +$1.88M 0.08% 234
2020
Q2 		– Sell
-3,100
Closed -$278K – 1165
2020
Q1 		$278K Buy
+3,100
New +$304K 0.02% 585
2019
Q4 		– Sell
-16,037
Closed -$1.57M – 1071
2019
Q3 		$1.57M Buy
16,037
+14,249
+797% +$1.61M 0.14% 193
2019
Q2 		$234K Buy
+1,788
New +$230K 0.02% 578
2017
Q2 		– Sell
-2,364
Closed -$287K – 907
2017
Q1 		$287K Buy
2,364
+502
+27% +$64.7K 0.05% 447
2016
Q4 		$228K Sell
1,862
-254
-12% -$31.1K 0.05% 548
2016
Q3 		$259K Buy
+2,116
New +$272K 0.06% 440

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Boothbay Fund Management's ALXN Position: Q3 2021 in Review

Boothbay Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 52,296 shares — an estimated $9.61M sold.

Boothbay Fund Management first reported a position in ALXN in Q3 2016 and held it in 9 quarters. The position peaked at $9.61M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Boothbay Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 52,296 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.61M.
  • Boothbay Fund Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • Boothbay Fund Management's Alexion Pharmaceuticals position peaked at $9.61M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.